LLY

991.49

+2.09%↑

JNJ

225.73

+1.86%↑

ABBV

209.23

+2.89%↑

UNH

392.08

+2.61%↑

AZN

184.92

+1.18%↑

LLY

991.49

+2.09%↑

JNJ

225.73

+1.86%↑

ABBV

209.23

+2.89%↑

UNH

392.08

+2.61%↑

AZN

184.92

+1.18%↑

LLY

991.49

+2.09%↑

JNJ

225.73

+1.86%↑

ABBV

209.23

+2.89%↑

UNH

392.08

+2.61%↑

AZN

184.92

+1.18%↑

LLY

991.49

+2.09%↑

JNJ

225.73

+1.86%↑

ABBV

209.23

+2.89%↑

UNH

392.08

+2.61%↑

AZN

184.92

+1.18%↑

LLY

991.49

+2.09%↑

JNJ

225.73

+1.86%↑

ABBV

209.23

+2.89%↑

UNH

392.08

+2.61%↑

AZN

184.92

+1.18%↑

Inicio・Lista de Acciones・Innoviva Inc

Innoviva Inc

Abierto

SectorSanidad

22.61 1.07

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

22.26

Máximo

23.1

Métricas clave
By Trading Economics
Ingresos	152M 242M
Ventas	10M 118M
P/B Media del Sector	7.009 49.8
Margen de beneficios	204.74
Empleados	159
EBITDA	100M 208M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+53.64% upside

Dividendos
By Dow Jones
Próximas Ganancias	12 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	43M 1.7B
Apertura anterior	21.54
Cierre anterior	22.61

Noticias sobre sentimiento de mercado

By Acuity

30%

70%

106 / 346 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

18.57 / 18.75 Soporte y Resistencia

Innoviva Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

11 may 2026, 22:15 UTC

Adquisiciones, fusiones, absorciones

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 may 2026, 23:46 UTC

Charlas de Mercado

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 may 2026, 23:44 UTC

Charlas de Mercado

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 may 2026, 23:33 UTC

Charlas de Mercado

Gold Rises on Possible Position Adjustments -- Market Talk

11 may 2026, 22:37 UTC

Charlas de Mercado

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 may 2026, 22:32 UTC

Ganancias

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 may 2026, 22:02 UTC

Charlas de Mercado

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 may 2026, 21:49 UTC

Ganancias

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 may 2026, 21:42 UTC

Charlas de Mercado

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 may 2026, 21:32 UTC

Adquisiciones, fusiones, absorciones

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 may 2026, 21:32 UTC

Adquisiciones, fusiones, absorciones

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 may 2026, 21:32 UTC

Adquisiciones, fusiones, absorciones

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 may 2026, 21:32 UTC

Adquisiciones, fusiones, absorciones

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 may 2026, 21:31 UTC

Adquisiciones, fusiones, absorciones

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 may 2026, 21:23 UTC

Adquisiciones, fusiones, absorciones

CSG Systems Sale to NEC Gets CFIUS Clearance

11 may 2026, 21:12 UTC

Ganancias

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 may 2026, 21:12 UTC

Ganancias

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 may 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

11 may 2026, 20:44 UTC

Ganancias

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 may 2026, 20:43 UTC

Ganancias

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 may 2026, 20:32 UTC

Ganancias

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 may 2026, 20:32 UTC

Ganancias

CleanSpark 2Q Rev $136.4M >CLSK

11 may 2026, 20:30 UTC

Ganancias

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 may 2026, 20:30 UTC

Ganancias

Steris 4Q Cont Ops EPS $2.24 >STE

11 may 2026, 20:30 UTC

Ganancias

Steris 4Q Rev $1.6B >STE

11 may 2026, 20:30 UTC

Ganancias

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 may 2026, 20:30 UTC

Ganancias

Steris 4Q Adj EPS $2.83 >STE

11 may 2026, 20:22 UTC

Acciones populares

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 may 2026, 19:37 UTC

Ganancias

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 may 2026, 19:32 UTC

Charlas de Mercado

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Comparación entre iguales

Cambio de precio

Innoviva Inc previsión

Precio Objetivo

By TipRanks

53.64% repunte

Estimación a 12 Meses

Media 34.6 USD 53.64%

Máximo 46 USD

Mínimo 18 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Innoviva Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Innoviva Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

18.57 / 18.75Soporte y Resistencia

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentimiento

By Acuity

106 / 346 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.